Clinical trial
Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid…
NCT00403416 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00403416 |
|---|---|
| Title | Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), in Renal Transplant Patients |
| Official title | 12-month Open Label, Randomized, Multicenter Study Evaluating Efficacy, Safety and Tolerability of Oral AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), vs. Mycophenolic Acid Plus Tacrolimus in de Novo Renal Transplant Recipients |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Transplantation |
| Intervention type | Drug |
| Interventions | AEB071, Mycophenolic Acid |
| Enrollment | 215 |
| Start date | Oct 1, 2006 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Nov 23, 2006 |
| Last update posted | Dec 17, 2020 |
| Countries | Canada, France, Germany, Italy, Spain, Switzerland, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: